Replies to post #116626 on Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Here here TOB ... K efficacy signals at this stage, Ph I, is HUGE.

Below, an excerpt from an earlier post of mine - link to a study that shows recent cancer drug approvals data -- how low/high the bar is as to PFS and OS across various cancers.

Overview
http://www.theguardian.com/society/2015/may/29/cancer-drugs-effectiveness-score-esmo-rankings

Full Study -- Note Table 7 / p. 33 for ovarian...

Based on today's tidbits as to K efficacy, and if results hold/improve across future K trials, well, vis a vis this comparative efficacy data, Kevetrin would have a great shot at getting approved.

Wouldn't be surprised if Breakthrough Therapy designation is the the next feather in its cap.

http://static.guim.co.uk/ni/1432986420413/Ann-Oncol-2015.pdf

Earlier post
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114164710

[To infinity and beyond!]

have not had the chance to look back over the ASCO report to see about the timing of doses but I would guess that there is at least a couple of 750 mg ovarian CA patients who have had 3 month scans, but maybe not 6 month scans

But I do not know

Do you know the cohort dates?

I could not agree more that some response at lower doses is EXCELLENT

[To infinity and beyond!]

It is amazing to think that patients treated with a drug with a 2 hour half life once weekly on 3 occasions would have any tumor stabilization, especially since those patients have already been through all the usual care with progression of disease